CNS Stimulant — Schedule 2 Controlled Drug (ADHD Treatment) Pregnancy: §4.6: data from a cohort study of approximately 3,400 first-trimester-exposed pregnancies do not suggest an increased risk of overall birth defects, but there was a small increased occurrence of cardiac malformations (pooled adjusted relative risk 1.3; 95% CI 1.0–1.6), corresponding to 3 additional infants with congenital cardiac malformations per 1,000 women treated in the first trimester. Cases of neonatal cardiorespiratory toxicity (foetal tachycardia, respiratory distress) have been reported spontaneously, and animal studies show reproductive toxicity at maternally toxic doses. Methylphenidate is not recommended during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy. Methylphenidate is excreted in human milk (infant doses 0.16% to 0.7% of the maternal weight-adjusted dosage); a risk to the suckling child cannot be excluded, so a decision must be made whether to discontinue breast-feeding or the medicine.

Methylphenidate

Brand names: Ritalin (immediate-release), Concerta XL, Equasym XL, Medikinet XL

Methylphenidate is a central nervous system stimulant and a first-line pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children and young people.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Adults new to methylphenidate: 18 mg once daily as the recommended starting dose, titrated in 18 mg increments at approximately weekly intervals

Route: Oral — prolonged-release tablet, swallowed whole with the aid of liquids; must not be chewed, divided or crushed; may be taken with or without food

Frequency: Once daily in the morning

Max: 72 mg daily in adults; 54 mg daily in children (for this prolonged-release product)

IMPORTANT SOURCE CAVEAT: this is a PROLONGED-RELEASE product — UK SPC (eMC) for Affenid XL 18 mg prolonged release tablets, §4.2 (https://www.medicines.org.uk/emc/product/14600/smpc). Immediate-release methylphenidate has different posology and must be sourced separately. Treatment must be initiated and supervised by a physician specialised in the treatment of ADHD (expert paediatrician, child and adolescent psychiatrist or adult psychiatrist). The SPC notes that this product may not be indicated in all patients with ADHD and that lower doses of short-acting methylphenidate formulations may be sufficient for patients new to methylphenidate. A 27 mg dosage strength is available for prescribing between the 18 mg and 36 mg dosages. PAEDIATRIC POSOLOGY (stated as fixed mg, not per kg, which is why paedDose is null): the recommended starting dose for children not currently taking methylphenidate, or on stimulants other than methylphenidate, is 18 mg once daily; the maximum daily dosage in children is 54 mg. Methylphenidate should not be used in children under the age of 6 years (safety and efficacy not established). CONVERSION FROM THREE-TIMES-DAILY METHYLPHENIDATE (§4.2 Table 1): 5 mg three times daily → 18 mg once daily; 10 mg three times daily → 36 mg once daily; 15 mg three times daily → 54 mg once daily; 20 mg three times daily → 72 mg once daily. Discontinue if improvement is not observed after appropriate dosage adjustment over a one-month period; reduce or discontinue if paradoxical aggravation of symptoms or other serious adverse events occur. PRE-TREATMENT SCREENING: baseline cardiovascular evaluation including blood pressure and heart rate, comprehensive history including family history of sudden cardiac/unexplained death, and pre-treatment height and weight on a growth chart; in adults new to methylphenidate cardiologist advice is needed prior to initiation where required by national practice. MONITORING: blood pressure and pulse at each dose adjustment and at least every 6 months; height, weight and appetite in children at least 6-monthly with a growth chart; weight recorded regularly in adults; psychiatric status at each dose adjustment, at least every 6 months and at every visit; monitor for diversion, misuse and abuse. LONG-TERM USE: re-evaluate periodically beyond 12 months with trial periods off medication, and de-challenge at least once yearly (for children, preferably during school holidays). ELDERLY: methylphenidate should not be used in the elderly.

Dose adjustments

Renal

Methylphenidate has not been studied in patients with renal impairment (§4.2). It has likewise not been studied in patients with hepatic impairment.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to methylphenidate or to any of the excipients
Glaucoma; phaeochromocytoma; hyperthyroidism or thyrotoxicosis
During treatment with non-selective, irreversible monoamine oxidase (MAO) inhibitors, or within a minimum of 14 days of discontinuing those drugs, due to the risk of hypertensive crisis
Diagnosis or history of severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder; diagnosis or history of severe and episodic (Type I) bipolar affective disorder that is not well controlled
Pre-existing cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies
Pre-existing cerebrovascular disorders — cerebral aneurysm, vascular abnormalities including vasculitis, or stroke

Side effects

Very common: headache; common: insomnia, nervousness
Common/metabolic: anorexia, decreased appetite, and moderately reduced weight and height gain during prolonged use in children
Common psychiatric: affect lability, aggression, agitation, anxiety, depression, irritability, abnormal behaviour, mood swings, tics, bruxism
Common nervous system: dizziness, dyskinesia, psychomotor hyperactivity, somnolence, paraesthesia, tension headache
Uncommon to rare: psychotic disorders and hallucinations, suicidal ideation, mania, convulsion, neuroleptic malignant syndrome, cerebrovascular disorders including cerebral haemorrhage and vasculitis, hypersensitivity reactions including angioneurotic oedema and anaphylaxis, thrombocytopenia and pancytopenia, and reports of abuse and dependence
NOTE: the §4.8 table was truncated at the source-fetch limit — this list is incomplete

Interactions

NOTE: the UK §4.5 section was not present in the fetched bundle — the first entry is from UK §4.3, the remainder are from the US label; source the full UK §4.5 separately
Non-selective irreversible MAO inhibitors — contraindicated during treatment and within a minimum of 14 days of discontinuation, due to the risk of hypertensive crisis (UK §4.3). The US label adds that potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary oedema and renal failure, and gives examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid and methylene blue
Antihypertensive drugs — methylphenidate may decrease their effectiveness; monitor blood pressure and heart rate and adjust the antihypertensive dose as needed (US label §7)
Halogenated anaesthetics — avoid use of methylphenidate on the day of surgery if halogenated anaesthetics will be used (US label §7)

Clinical monograph

How it works

It blocks the reuptake of dopamine and noradrenaline at the presynaptic transporter, increasing synaptic concentrations of these monoamines in the prefrontal cortex and other regions involved in attention and impulse control.

Prescribing in practice

Assess cardiovascular history and screen for significant cardiac disease before starting, as methylphenidate raises heart rate and blood pressure and is contraindicated in certain cardiac and psychiatric conditions.
Monitor height and weight, as growth may be suppressed during treatment, and review the continued need for therapy periodically including planned treatment-free reviews.
Initiation should be under a specialist in ADHD; titrate according to response and tolerability using a children's formulary and the SPC.

Monitoring

Monitor heart rate, blood pressure, height, weight, appetite, sleep and mental state (including emergence of tics, anxiety or psychiatric symptoms) at baseline and regularly during treatment.

Counselling the patient

Explain that the medicine helps with concentration and impulsivity but works alongside behavioural and educational support.
Report palpitations, chest pain, fainting, marked mood changes or new involuntary movements.
Appetite suppression and difficulty sleeping are common; giving doses earlier in the day and with or after food can help.

Evidence & guidelines

NICE recommends methylphenidate as a first-line medication for ADHD in children and young people when medication is indicated, supported by extensive randomised trial evidence including the MTA study.

Reference: NICE NG87 (ADHD); MHRA Methylphenidate Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways